Free Trial

Pyxis Oncology Q2 2024 Earnings Report

Pyxis Oncology logo
$0.91 -0.02 (-2.57%)
As of 04:00 PM Eastern

Pyxis Oncology EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Pyxis Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pyxis Oncology Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Pyxis Oncology Earnings Headlines

Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $9.20
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Stifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)
RBC Capital Remains a Buy on Pyxis Oncology (PYXS)
See More Pyxis Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pyxis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pyxis Oncology and other key companies, straight to your email.

About Pyxis Oncology

Pyxis Oncology (NASDAQ:PYXS), a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

View Pyxis Oncology Profile

More Earnings Resources from MarketBeat